4-氯-5-甲氧基-2-(2-吡啶)嘧啶 | 321432-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-5-甲氧基-2-(2-吡啶)嘧啶
• 中文别名: 4-氯-5-甲氧基-2-(2-吡啶基)嘧啶
• 英文名称: 4-chloro-5-methoxy-2-(pyridin-2-yl)pyrimidine
• 英文别名: 4-chloro-5-methoxy-2-(2-pyridinyl)pyrimidine；4-chloro-5-methoxy-2-pyridin-2-ylpyrimidine
• CAS: 321432-82-0
• 化学式: C₁₀H₈ClN₃O
• 分子量: 221.646
• InChiKey: BTHRCJACYHBCHX-UHFFFAOYSA-N

物化性质

• 熔点：
  168-171℃
• 沸点：
  260.8±22.0 °C(Predicted)
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-氯-5-甲氧基-2-(2-吡啶)嘧啶 以 异丙醇 为溶剂， 生成 isopropyl-(5-methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-ammonium fumarate
  参考文献：
  名称：

  USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS

  摘要：

  这项发明涉及一种TRPM8调节剂，用于在皮肤或粘膜上产生降温效果。

  公开号：

  US20120263659A1
• 作为产物：
  描述：

  2-氰基吡啶 在 sodium methylate 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 4-氯-5-甲氧基-2-(2-吡啶)嘧啶
  参考文献：
  名称：

  USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS

  摘要：

  这项发明涉及一种TRPM8调节剂，用于在皮肤或粘膜上产生降温效果。

  公开号：

  US20120263659A1

文献信息

• Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US20030069239A1

  公开（公告）日：2003-04-10

  The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1 wherein A, Ar 1 , Ar 2 , R 1 and R 3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及被一般式I所代表的取代的2-芳基-4-芳基氨基嘧啶及其类似物： 其中A，Ar1，Ar2，R1和R3在此处被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于诱导在出现未受控制的异常细胞生长和扩散的各种临床病况中的细胞死亡。
• Novel Pyrimidine- And Triazine-Hepcidine Antagonists
  申请人：Dürrenberger Franz

  公开号：US20120202806A1

  公开（公告）日：2012-08-09

  The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

  本发明涉及新的肝铁蛋白拮抗剂，包含它们的药物组合物以及将其用作药物的用途，特别是用于治疗铁代谢紊乱，如特别是铁缺乏病和贫血，特别是与慢性炎症性疾病相关的贫血（ACD：慢性疾病性贫血和AI：炎症性贫血）。
• Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cytovia, Inc.

  公开号：US20040097503A1

  公开（公告）日：2004-05-20

  The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1 wherein A, Ar 1 , Ar 2 , R 1 and R 3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的2-芳基-4-芳氨基嘧啶及其类似物，由通式I表示：其中A、Ar1、Ar2、R1和R3如本文所定义。本发明还涉及发现具有I式化合物的活化剂和凋亡诱导剂。本发明的化合物可用于在各种临床情况下诱导细胞死亡，其中出现了不受控制的异常细胞的生长和扩散。
• Discovery of substituted 4-anilino-2-arylpyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 2. Structure–activity relationships of the 2-aryl group
  作者：Nilantha Sirisoma、Azra Pervin、Bao Nguyen、Candace Crogan-Grundy、Shailaja Kasibhatla、Ben Tseng、John Drewe、Sui Xiong Cai

  DOI：10.1016/j.bmcl.2009.02.074

  日期：2009.4

  As a continuation of our efforts to discover and develop the apoptosis inducing 4-anilino-2-(2-pyridyl) pyrimidines as potential anticancer agents, we explored replacing the 2-pyridyl group by other aryl groups. SAR studies showed that the 2-pyridyl group can be replaced by a 3-pyridyl, 4-pyridyl and 2-pyrazinyl group, and that the SAR for the anilino group was similar to that of the 2-pyridyl series. However, replacement of the 2-pyridyl group by a phenyl group, a 3,5-dichloro-4-pyridyl group, or a saturated ring led to inactive compounds. Several potent compounds, including 2f, 3d, 3j and 4a, with EC50 values of 0.048-0.024 mu M in the apoptosis induction assay against T47D cells, were identified through the SAR studies. In a tubulin polymerization assay, compound 2f, which was active against all the three cell lines tested (T47D, HTC116 and SNU398), inhibited tubulin polymerization with an IC50 value of 0.5 mu M, while compound 2a, which was active against T47D cells but not active against HTC116 and SNU398 cells, was not active in the tubulin assay at up to 50 mu M. (c) 2009 Elsevier Ltd. All rights reserved.
• Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors
  作者：Junji Miyata、Chiyoshi Kasahara、Toru Asano、Shinji Ito、Norio Seki、Yasuko Kato、Noriyuki Morikawa、Kazuyoshi Nozaki、Kouji Nishimura、Hisashi Akamatsu、Yusuke Taguchi、Tomonori Yamaguchi、Yoshito Abe、Mitsuru Ohkubo、Toshihiro Watanabe、Mitsuaki Ohta、Makoto Takeuchi

  DOI：10.1016/j.bmcl.2012.06.087

  日期：2012.9

  An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl) pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position of the benzyl group ameliorated in vitro activity, and further fluorination of the benzyl group improved microsomal stability in rodents. Representative members of this series, compounds 20 and 23, exhibited efficacy in RANKL-induced osteopenic mice when administered orally at 0.3 mg/kg. (C) 2012 Elsevier Ltd. All rights reserved.